Compare VTYX & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTYX | NXP |
|---|---|---|
| Founded | 2018 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.6M | 743.2M |
| IPO Year | 2021 | N/A |
| Metric | VTYX | NXP |
|---|---|---|
| Price | $8.17 | $14.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.60 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 70.0K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $26.81 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $12.91 |
| 52 Week High | $10.55 | $14.89 |
| Indicator | VTYX | NXP |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 44.76 |
| Support Level | $8.39 | $14.23 |
| Resistance Level | $9.13 | $14.38 |
| Average True Range (ATR) | 0.63 | 0.13 |
| MACD | -0.25 | -0.01 |
| Stochastic Oscillator | 20.35 | 27.00 |
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.